Baseline demographics and clinical characteristics of TNFi-naive and TNFi-experienced patients with PsA overall and in those who continued versus discontinued their index TNFi by the first follow-up visit
| Characteristic | Total population (N=318) | TNFi naive | TNFi experienced | ||||
| Overall (n=171) | Continued (n=122) | Discontinued (n=49) | Overall (n=147) | Continued (n=88) | Discontinued (n=59) | ||
| Age, mean (SD), years | 53.6 (13.7) | 53.0 (15.2) | 53.6 (16.2) | 51.5 (12.2) | 54.3 (11.6) | 54.0 (11.8) | 54.9 (11.4) |
| Female, n (%) | 179 (56.8) | 94 (55.3) | 64 (52.5) | 30 (62.5) | 85 (58.6) | 45 (51.7) | 40 (69.0)* |
| White, n (%) | 288 (90.6) | 159 (93.0) | 112 (91.8) | 47 (95.9) | 129 (87.8) | 78 (88.6) | 51 (86.4) |
| BMI, mean (SD), kg/m2 | 32.4 (7.6) | 32.1 (8.0) | 32.1 (8.1) | 32.1 (8.0) | 32.7 (7.1) | 32.0 (7.3) | 33.6 (6.8) |
| BMI (in kg/m2) classification, n (%) | |||||||
| Normal/underweight (<25.0) | 41 (13.8) | 27 (17.2) | 20 (17.9) | 7 (15.6) | 14 (9.9) | 11 (13.1) | 3 (5.3) |
| Overweight (25.0 to <30.0) | 83 (27.9) | 40 (25.5) | 24 (21.4) | 16 (35.6) | 43 (30.5) | 29 (34.5) | 14 (24.6) |
| Obese (≥30.0) | 174 (58.4) | 90 (57.3) | 68 (60.7) | 22 (48.9) | 84 (59.6) | 44 (52.4) | 40 (70.2) |
| Insurance type, n (%) | |||||||
| Private | 249 (78.5) | 136 (79.5) | 93 (76.2) | 43 (87.8) | 113 (77.4) | 70 (80.5) | 43 (72.9) |
| Medicare | 21 (6.6) | 12 (7.0) | 11 (9.0) | 1 (2.0) | 9 (6.2) | 3 (3.5) | 6 (10.2) |
| Medicaid | 21 (6.6) | 12 (7.0) | 9 (7.4) | 3 (6.1) | 9 (6.2) | 6 (6.9) | 3 (5.1) |
| Medicare+private | 21 (6.6) | 8 (4.7) | 7 (5.7) | 1 (2.0) | 13 (8.9) | 8 (9.2) | 5 (8.5) |
| None | 5 (1.6) | 3 (1.8) | 2 (1.6) | 1 (2.0) | 2 (1.4) | 0 | 2 (3.4) |
| Disease duration, mean (SD), years | 11.2 (10.0) | 9.5 (9.7) | 9.7 (9.8) | 8.8 (9.6) | 13.3 (10.0)† | 14.1 (9.4) | 12.1 (10.9) |
| History of comorbid conditions, n (%) | |||||||
| Diabetes mellitus | 43 (13.5) | 21 (12.3) | 15 (12.3) | 6 (12.2) | 22 (15.0)† | 13 (14.8) | 9 (15.3) |
| Cardiovascular disease‡ | 45 (14.2) | 18 (10.5) | 15 (12.3) | 3 (6.1) | 27 (18.4) | 17 (19.3) | 10 (17.0) |
| Any cancer§ | 25 (7.9) | 13 (7.6) | 10 (8.2) | 3 (6.1) | 12 (8.2) | 7 (8.0) | 5 (8.5) |
| Serious infection¶ | 25 (7.9) | 12 (7.0) | 8 (6.6) | 4 (8.2) | 13 (8.8) | 8 (9.1) | 5 (8.5) |
| Current MTX use, n (%) | 157 (49.4) | 92 (53.8) | 63 (51.6) | 29 (59.2) | 65 (44.2) | 40 (45.5) | 25 (42.4) |
| History of prednisone use, n (%) | 71 (22.3) | 30 (17.5) | 22 (18.0) | 8 (16.3) | 41 (27.9)† | 30 (34.1) | 11 (18.6) |
| Current prednisone use, n (%) | 27 (8.5) | 12 (7.0) | 8 (6.6) | 4 (8.2) | 15 (10.2) | 8 (9.1) | 7 (11.9) |
*P<0.05 for the comparison between patients who continued versus discontinued their index TNFi within the TNFi-naive or TNFi-experienced cohort.
†P<0.05 for the comparison between the overall populations of TNFi-naive and TNFi-experienced patients.
‡Combined histories of myocardial infarction, acute coronary syndrome, coronary artery disease, congestive heart failure, peripheral artery disease, cardiac revascularisation procedure, ventricular arrhythmia, cardiac arrest, unstable angina, stroke, transient ischaemic attack, pulmonary embolism, carotid artery disease, deep venous thrombosis or other cardiovascular event.
§Excludes non-melanoma of the skin.
¶Includes infections that led to hospitalisation or intravenous antibiotics: joint/bursa, cellulitis, sinusitis, diverticulitis, sepsis, pneumonia, bronchitis, gastroenteritis, meningitis, urinary tract, upper respiratory tract or infection of other specified site.
BMI, body mass index;MTX, methotrexate;PsA, psoriatic arthritis;TNFi, tumour necrosis factor inhibitor.